News Column

Recent Findings from University of Copenhagen Has Provided New Information about Vaccines (Activation of the NLRP3 inflammasome is not a feature of...

August 13, 2014



Recent Findings from University of Copenhagen Has Provided New Information about Vaccines (Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants)

By a News Reporter-Staff News Editor at Vaccine Weekly -- A new study on Immunization is now available. According to news reporting from Copenhagen, Denmark, by NewsRx journalists, research stated, "Particulate vaccine formulations, designed to improve the delivery of antigens to antigen-presenting cells (APCs) and to stimulate an immune response, have been shown to activate the NLRP3 inflammasome. This leads to the processing and secretion of interleukin (IL)-1 beta, which supports the recruitment of pro-inflammatory immune cells into the tissue and can therefore be beneficial for vaccine potency."

The news correspondents obtained a quote from the research from the University of Copenhagen, "Recent work suggested that this may be a common mechanism of action for all particulate formulations. The aim of this study was to investigate whether the activation of the NLRP3 inflammasome was common to many delivery systems. We prepared polymer-based chitosan nanoparticles (CNPs), lipid-based cubosomes, a water in oil emulsion of incomplete Freund's adjuvant (IFA) and alum formulations and examined inflammasome activation in vitro using murine bone-marrow-derived dendritic cells and human peripheral blood mononuclear cells and in vivo in mice. The formulations differed in their morphology, size and zeta-potential. Only the positively charged particles (CNPs and alum) were able to activate the inflammasome and increase the secretion of IL-1 beta. A decrease in the activation of the inflammasome with these particulates was observed when cathepsin B-mediated effects were blocked, implying a role of lysosomal rupture in the activation process."

According to the news reporters, the research concluded: "These findings demonstrate a role for the surface charge of particulates in the activation of the NLRP3 inflammasome, which should be considered when designing a novel vaccine formulation."

For more information on this research see: Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunology and Cell Biology, 2014;92(6):535-542. Immunology and Cell Biology can be contacted at: Nature Publishing Group, 75 Varick St, 9TH Flr, New York, NY 10013-1917, USA. (Nature Publishing Group - www.nature.com/; Immunology and Cell Biology - www.nature.com/icb/)

Our news journalists report that additional information may be obtained by contacting S. Neumann, University of Copenhagen, Dept. of Pharm, Copenhagen, Denmark. Additional authors for this research include K. Burkert, R. Kemp, T. Rades, P.R. Dunbar and S. Hook (see also Immunization).

Keywords for this news article include: Europe, Denmark, Vaccines, Copenhagen, Immunization, Biological Products

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Vaccine Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters